ACC 006
Alternative Names: ACC-006Latest Information Update: 28 Sep 2024
Price :
$50 *
At a glance
- Originator Jiangsu Aidea Pharmaceutical
- Class Antineoplastics
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- No development reported Non-small cell lung cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Non-small-cell-lung-cancer in China
- 17 Aug 2020 Jiangsu Aidea Pharmaceutical and Sun Yat-Sen University Cancer Center plans a phase II trial for Non-small cell lung cancer (Combination therapy, First-line therapy, Inoperable/Unresectable, Late-stage disease, Metastatic disease, Recurrent) in China (ChiCTR2000035558)